What we do

Blackbird Laboratories is an independent, nonprofit and next-generation life sciences incubator, dedicated to transforming breakthrough research into scalable, venture-ready biotech companies. We are committed to advancing a better future for patients facing unmet medical needs.

Incubate life sciences

We transform research breakthroughs into scalable, venture-ready biotech companies through operational support, founder-facing resources, and strategic capital. We are dedicated to advancing a better future for patients in need of life-changing therapies.

Accelerate Baltimore biotech

As a nonprofit biotech incubator, we serve as a company creation engine supporting scientists, building new ventures, and attracting top-tier talent.

Build from research to startup

We collaborate with scientists from world-class institutions and early-stage founders in the greater Baltimore region to transform innovative research into life-changing therapies through company creation.

We seek to bridge the gap between pioneering science and industry

Blackbird Laboratories collaborates with world-class institutions and scientific partners to propel our portfolio of innovative technologies toward startup formation through our science and business strategy, program management, and capital.

Operating model

Ways to engage with us

Academics

Collaborate on pioneering research projects

VCs

Partner on investing in Seed and Series A stage companies

Entrepreneurs

Lead our portfolio companies

Pharma

Initiate strategic collaborations

12 Scientists
2 Admin
0
TEAM

Experienced team
of biotech operators

Projects evaluated
0 +
PROJECTS & COMPANIES
  • 19 Funded Projects
  • 18 Portfolio Companies
$ Committed
0 M
RESOURCES
  • $33M Research + Infrastructure
  • $37M Investments
ft 2
0 k
LAB SPACE

Incubator opening
in Q1-2026

Top-tier institutions
0 +
PARTNERS

Johns Hopkins
UM Baltimore
Lieber Institute
Stanford University
UC San Diego

Top-tier VCs
0 +

Foresite Capital
Cure Ventures
Catalio Capital
PTX Capital                                      Decheng Capital
& others